Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Metastatic melanoma has a poor prognosis with high resistance to chemotherapy and radiation. Recently, the anti-CTLA-4 antibody ipilimumab has demonstrated clinical efficacy, being the first agent to significantly prolong the overall survival of inoperable stage III/IV melanoma patients. A major aim of patient immune monitoring is the identification of biomarkers that predict clinical outcome. We studied circulating myeloid-derived suppressor cells (MDSC) in ipilimumab-treated patients to detect alterations in the myeloid cell compartment and possible correlations with clinical outcome. Lin(-) CD14(+) HLA-DR(-) monocytic MDSC were enriched in peripheral blood of melanoma patients compared to healthy donors (HD). Tumor resection did not significantly alter MDSC frequencies. During ipilimumab treatment, MDSC frequencies did not change significantly compared to baseline levels. We observed high inter-patient differences. MDSC frequencies in ipilimumab-treated patients were independent of baseline serum lactate dehydrogenase levels but tended to increase in patients with severe metastatic disease (M1c) compared to patients with metastases in skin or lymph nodes only (M1a), who had frequencies comparable to HD. Interestingly, clinical responders to ipilimumab therapy showed significantly less lin(-) CD14(+) HLA-DR(-) cells as compared to non-responders. The data suggest that the frequency of monocytic MDSC may be used as predictive marker of response, as low frequencies identify patients more likely benefitting from ipilimumab treatment. Prospective clinical trials assessing MDSC frequencies as potential biomarkers are warranted to validate these observations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“both a low baseline frequency of MDSCs and a low frequency of MDSCs in the blood of patients with melanoma following ipilimumab treatment were associated with favorable therapy outcome (134, 169-171).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [169]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“patients with cancer who have high levels of circulating MDSCs have been found to respond poorly to checkpoint blockade”
From LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer (2018) · cites this paper as Meyer et al., 2014
Experimental — accuracy not yet measuredIn the citing paper
“lower numbers of MDSCs in melanoma patients were associated with a better response to Ipilimumab (CTLA-4 antibody) (Meyer et al., 2014).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Meyer et al., 2014
In the citing paper
“numerous studies of patients with cancer have indeed found that these myeloid cell subsets, whether in the tumor or in peripheral tissues, were negatively correlated with effective ICI therapy (134, 161, 168-171).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [169]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 5×
“However, autoimmune responses are also promoted, as 10–15 % of patients develop severe grade 3–4 immune-related adverse events [8].”
BackgroundInfluentialThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“Recently, the fully humanized anti-CTLA-4 antibody ipilimumab was reported to increase overall survival of stage III/IV metastatic melanoma patients [8, 9].”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“Different malignancies favor the accumulation of different MDSC phenotypes in patients [29].”
BackgroundWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156 · cited 1×
“About 50 % of melanomas express BRAF-activating mutations [4], which are V600E and V600K substitutions in 95 % of cases [5].”
Background
Cited by
Items 201–300 of 617
The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients
Tobin, R. P., Davis, D. M., Jordan, K. R., & McCarter, M. D. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1016-449r · Cited by 57
Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
Zhang, N., Li, W., Ye, M., Kang, C., & You, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.592612 · Cited by 57
Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC
Qu, J., Jiang, M., Wang, L., Zhao, D., Qin, K., Wang, Y., Tao, J., & Zhang, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109996 · Cited by 56
Du, Y., Peng, Q., Cheng, D., Pan, T. S., Sun, W., Wang, H., Ma, X., He, R.-R., Zhang, H., Cui, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27936-8 · Cited by 56
Bjoern, J., Iversen, T. Z., Nitschke, N. J., Andersen, M. H., & Svane, I. M. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.05.010 · Cited by 55
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some
Rowdo, F. P. M., Barón, A., Urrutia, M., & Mordoh, J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00127 · Cited by 55
Cancer cell-derived type I interferons instruct tumor monocyte polarization
Kwart, D., He, J., Srivatsan, S., Lett, C., Golubov, J., Oswald, E. M., Poon, P., Ye, X., Waite, J. C., Zaretsky, A. G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111769 · Cited by 55
Schiza, A., Wenthe, J., Mangsbo, S. M., Eriksson, E., Nilsson, A., Tötterman, T. H., Loskog, A., & Ullenhag, G. J. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1182-z · Cited by 53
Molecular Pathways: Myeloid Complicity in Cancer
Stromnes, I. M., Greenberg, P. D., & Hingorani, S. R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0866 · Cited by 52
Xue, G., Wang, Z., Zheng, N., Fang, J., Mao, C., Li, X., Jin, G., Ming, X., & Lu, Y. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00799-6 · Cited by 52
Zhang, B., Wang, C., Wu, H., Wang, F., Chai, Y., Hu, Y., Wang, B., Zhou, Y. L., Xia, R., Xu, R., et al. (2023) · 癌症:英文版 · doi:10.1002/cac2.12476 · Cited by 52
Retseck, J., Nasr, A., Lin, Y., Lin, H., Mendiratta, P., Butterfield, L. H., & Tarhini, A. A. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1563-y · Cited by 51
Therapeutic prospects of targeting myeloid‐derived suppressor cells and immune checkpoints in cancer
Toor, S. M., & Elkord, E. (2018) · Immunology and Cell Biology · doi:10.1111/imcb.12054 · Cited by 51
Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
Zhuang, Y., Liu, C. X., Liu, J., & Li, G. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s239398 · Cited by 50
Arasanz, H., Bocanegra, A., Morilla, I., Fernández‐Irigoyen, J., Martínez-Aguillo, M., Teijeira, L., Garnica, M., Blanco, E., Chocarro, L., Ausín, K., et al. (2022) · Cancers · doi:10.3390/cancers14163846 · Cited by 50
Linking Serine/Glycine Metabolism to Radiotherapy Resistance
Sánchez‐Castillo, A., Vooijs, M., & Kampen, K. R. (2021) · Cancers · doi:10.3390/cancers13061191 · Cited by 50
de Coaña, Y. P., Wolodarski, M., Àvila, I. V. D. H., Nakajima, T., Rentouli, S., Lundqvist, A., Masucci, G. V., Hansson, J., & Kiessling, R. W. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1786888 · Cited by 50
Chicas-Sett, R., Zafra, J., Rodríguez‐Abreu, D., Castilla-Martinez, J., Benítez, G., Salas-Salas, B., Hernández, S., Lloret, M., Onieva, J. L., Barragán, I., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.05.013 · Cited by 50
ERBB1/2/3 Expression, Prognosis, and Immune Infiltration in Cutaneous Melanoma
Liu, S., Geng, R., Lin, E., Zhao, P., & Chen, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.602160 · Cited by 50
Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy
Ginefra, P., Lorusso, G., & Vannini, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124441 · Cited by 49
Ma, B., Wells, A. H., & Clark, A. M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.021 · Cited by 49
Zeng, W., Liu, H., Mao, Y., Jiang, S., Hao, Y., Zhang, Z., Wang, M., & Zong, Z. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5673 · Cited by 49
Qiu, H. Y., Zmina, P. M., Huang, A. Y.-C., Askew, D., & Bedogni, B. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.024 · Cited by 49
The immunosuppressive landscape in tumor microenvironment
Liu, W., Zhou, H., Lai, W., Hu, C., Xu, R., Gu, P., Luo, M., Zhang, R., & Li, G. (2024) · Immunologic Research · doi:10.1007/s12026-024-09483-8 · Cited by 48
Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review
Haibe, Y., Husseini, Z. E., Sayed, R. E., & Shamseddine, A. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176176 · Cited by 47
Determinants of Resistance to Checkpoint Inhibitors
Tran, L. L., & Theodorescu, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051594 · Cited by 47
The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers
Ren, R., Xiong, C., Ma, R., Wang, Y., Yue, T., Yu, J., & Shao, B. (2023) · MedComm · doi:10.1002/mco2.323 · Cited by 47
Bayık, D., Tross, D., & Klinman, D. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00608 · Cited by 47
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
Tai, D. W.-M., Choo, S. P., & Chew, V. (2019) · Cancers · doi:10.3390/cancers11121926 · Cited by 46
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition
Friedman, C. F., & Postow, M. A. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0509-x · Cited by 46
The tumour immune landscape and its implications in cutaneous melanoma
Attrill, G. H., Ferguson, P. M., Palendira, U., Long, G. V., Wilmott, J. S., & Scolyer, R. A. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12926 · Cited by 46
Tan, Q., Yin, S., Zhou, D., Chi, Y., Man, X., & Li, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.779786 · Cited by 46
Hoffmann, S. H. L., Reck, D. I., Maurer, A., Fehrenbacher, B., Sceneay, J., Poxleitner, M., Öz, H. H., Ehrlichmann, W., Reischl, G., Fuchs, K., et al. (2019) · Theranostics · doi:10.7150/thno.33275 · Cited by 46
Monitoring the immune competence of cancer patients to predict outcome
Chang, S., Kohrt, H. E. K., & Maecker, H. T. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1521-3 · Cited by 46
Yin, W., Song, Y. Y., Liu, Q., Wu, Y., & He, R. (2017) · Immunology · doi:10.1111/imm.12768 · Cited by 46
The Discovery of Biomarkers in Cancer Immunotherapy
George, A. P., Kuzel, T. M., Zhang, Y., & Zhang, B. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.015 · Cited by 45
Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies
Vu, S. H., Vetrivel, P., Kim, J., & Lee, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810906 · Cited by 45
Ao, Z., Wu, Z., Cai, H., Hu, L., Li, X., Kaurich, C., Chang, J., Gu, M., Cheng, L., Lü, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202201478 · Cited by 45
Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer
Jenkins, R. W., Thummalapalli, R., Carter, J., Cañadas, I., & Barbie, D. A. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-060116-022926 · Cited by 44
Bad company: Microenvironmentally mediated resistance to targeted therapy in melanoma
Almeida, F. V., Douglass, S. M., Fane, M. E., & Weeraratna, A. T. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12736 · Cited by 44
Relecom, A., Merhi, M., Inchakalody, V. P., Shahab Uddin, M. S., Rinchai, D., Bedognetti, D., & Dermime, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01872-3 · Cited by 44
HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling
Arkhypov, I., Kurt, F. G. Ö., Bitsch, R., Novak, D., Petrova, V., Lasser, S., Hielscher, T., Groth, C., Lepper, A., Hu, X., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005551 · Cited by 44
Ouwerkerk, W., van den Berg, M., van der Niet, S., Limpens, J., & Luiten, R. M. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000589 · Cited by 44
Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance
Li, Y., Liu, J., Gao, L., Liu, Y., Meng, F., Li, X., & Qin, F. X.-F. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.006 · Cited by 44
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
Li, Z., Sun, G., Sun, G., Cheng, Y., Wu, L., Wang, Q., Lv, C., Zhou, Y., Xia, Y., & Tang, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.771335 · Cited by 43
Implications of metabolism-driven myeloid dysfunctions in cancer therapy
Strauss, L., Guarneri, V., Gennari, A., & Sica, A. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00556-w · Cited by 43
Adeshakin, A. O., Adeshakin, F. O., Yan, D., & Wan, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.781660 · Cited by 43
Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy
Yuan, S., Liu, Y., Till, B. G., Song, Y., & Wang, Z. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.563653 · Cited by 42
van Wigcheren, G. F., de Haas, N., Mulder, T. A., Horrevorts, S. K., Bloemendal, M., Bree, S. H.-D., Mao, Y., Kiessling, R. W., van Herpen, C. M. L., Flórez‐Grau, G., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1935557 · Cited by 42
Good, L., Benner, B. N., & Carson, W. E. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02908-5 · Cited by 42
Role of myeloid-derived suppressor cells in metastasis
Cole, K., Pravoverov, K., & Talmadge, J. E. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09947-x · Cited by 41
Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy
Clappaert, E. J., Murgaski, A., Damme, H. V., Kiss, M., & Laoui, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02250 · Cited by 41
Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy
de Coaña, Y. P., Masucci, G. V., Hansson, J., & Kiessling, R. W. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1570-7 · Cited by 40
Immunosenescence and cancer: Opportunities and challenges
Fu, Z., Xu, H., Yue, L., Zheng, W., Pan, L., Gao, F., & Liu, X. (2023) · Medicine · doi:10.1097/md.0000000000036045 · Cited by 40
Hernandez, C., Arasanz, H., Chocarro, L., Bocanegra, A., Zuazo, M., Fernández-Hinojal, G., Blanco, E., Vera, R., Escors, D., & Kochan, G. T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072411 · Cited by 40
Shi, H., Li, K., Ni, Y., Liang, X., & Zhao, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.707198 · Cited by 40
Mechanisms of Resistance to Checkpoint Blockade Therapy
Shi, H., Lan, J., & Yang, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_5 · Cited by 40
Hu, T., Zhai, J., Yang, Z., Peng, J., Wang, C., Liu, X., Li, Y., Yao, J., Chen, F., Li, H., et al. (2025) · MedComm · doi:10.1002/mco2.70231 · Cited by 40
Ancel, J., Dormoy, V., Nawrocki‐Raby, B., Dalstein, V., Durlach, A., Dewolf, M., Gilles, C., Polette, M., & Deslée, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1171649 · Cited by 40
Chattopadhyay, A., Yang, X., Mukherjee, P., Sulaiman, D., Fogelman, H. R., Grijalva, V. R., Dubinett, S. M., Wasler, T. C., Paul, M. K., Salehi‐Rad, R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26755-0 · Cited by 40
Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy
Lee, J., & Kim, E. H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1233376 · Cited by 39
Sun, S. H., Benner, B. N., Savardekar, H., Lapurga, G., Good, L., Abood, D., Nagle, E., Duggan, M. C., Stiff, A. R., DiVincenzo, M. J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.740890 · Cited by 39
Sei, S., Ahadova, A., Keskin, D. B., Bohaumilitzky, L., Gebert, J. F., Doeberitz, M. V. K., Lipkin, S. M., & Kloor, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1147590 · Cited by 38
Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma
Garutti, M., Bonin, S., Buriolla, S., Bertoli, E., Pizzichetta, M. A., Zalaudek, I., & Puglisi, F. (2021) · Cancers · doi:10.3390/cancers13081819 · Cited by 38
Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy
Zhang, M., Yang, H. J., Hua, W., Zhong, L., Xu, Z., & Qian, Q. (2019) · Frontiers of Medicine · doi:10.1007/s11684-018-0678-0 · Cited by 38
Wang, Q., Shen, X., Chen, G., & Du, J. (2023) · International Journal of Cancer · doi:10.1002/ijc.34464 · Cited by 38
Tissue‐specific tumor microenvironments influence responses to immunotherapies
Oliver, A. J., Davey, A. S., Keam, S. P., Mardiana, S., Chan, J. D., von Scheidt, B., Beavis, P. A., House, I. G., Audenaerde, J. R. M. V., Darcy, P. K., et al. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1094 · Cited by 38
van Elsas, M. J., Labrie, C., Etzerodt, A., Charoentong, P., Thans, J. J. C. V. S., van Hall, T., & van der Burg, S. H. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006433 · Cited by 38
A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Owen, D. H., Benner, B. N., Wei, L., Sukrithan, V., Goyal, A., Zhou, Y., Pilcher, C., Suffren, S., Christenson, G., Curtis, N., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1552 · Cited by 38
Biomarkers related to immune checkpoint inhibitors therapy
Li, N., Hou, X., Huang, S., Tai, R., Lei, L., Li, S., Abuliz, A., Wang, G., & Yang, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112470 · Cited by 37
Predictive factors of response to immunotherapy—a review from the Spanish Melanoma Group (GEM)
On behalf of the Spanish Melanoma Group (GEM), Espinosa, E., Márquez‐Rodas, I., Soria, A., Berrocal, A., Manzano, J. L., González‐Cao, M., & Martín‐Algarra, S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.08.10 · Cited by 37
Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
Fenton, S. E., Sosman, J. A., & Chandra, S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.28 · Cited by 37
Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
Liu, T. W. B., Gammon, S. T., Yang, P., Ma, W., Wang, J., & Piwnica-Worms, D. R. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005837 · Cited by 37
Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy
Lecis, D., Sangaletti, S., Colombo, M. P., & Chiodoni, C. (2019) · Cancers · doi:10.3390/cancers11050624 · Cited by 37
Liberini, V., Mariniello, A., Righi, L., Capozza, M., Delcuratolo, M. D., Terreno, E., Farsad, M., Volante, M., Novello, S., & Deandreis, D. (2021) · Cancers · doi:10.3390/cancers13184543 · Cited by 36
Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer
Camisaschi, C., Vallacchi, V., Vergani, E., Tazzari, M., Ferro, S., Tuccitto, A., Kuchuk, O., Shahaj, E., Sulsenti, R., Castelli, C., et al. (2016) · Vaccines · doi:10.3390/vaccines4040038 · Cited by 36
The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma
Fattore, L., Ruggiero, C. F., Liguoro, D., Castaldo, V., Catizone, A., Ciliberto, G., & Mancini, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.645069 · Cited by 36
Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs
Drakes, M. L., Czerlanis, C. M., & Stiff, P. J. (2020) · Cancers · doi:10.3390/cancers12113301 · Cited by 36
Li, C., Donninger, H., Eaton, J., & Yaddanapudi, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01525 · Cited by 35
Zhang, T., Harrison, M. R., O’Donnell, P. H., Alva, A. S., Hahn, N. M., Appleman, L. J., Cetnar, J. P., Burke, J. M., Fleming, M. T., Milowsky, M. I., et al. (2020) · Cancer · doi:10.1002/cncr.33067 · Cited by 35
Douglass, S. M., Fane, M. E., Sanseviero, E., Ecker, B. L., Kugel, C. H., Behera, R., Kumar, V., Tcyganov, E. N., Yin, X., Liu, Q., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1238 · Cited by 35
Strategies to overcome resistance to immune checkpoint blockade in lung cancer
Attili, I., Tarantino, P., Passaro, A., Stati, V., Curigliano, G., & de Marinis, F. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.035 · Cited by 34
Baltussen, J. C., Welters, M. J. P., Verdegaal, E. M. E., Kapiteijn, E., Schrader, A. M. R., Slingerland, M., Liefers, G., van der Burg, S. H., Portielje, J. E. A., & de Glas, N. A. (2021) · Cancers · doi:10.3390/cancers13246366 · Cited by 34
Mechanisms of Resistance to Immune Checkpoint Antibodies
Ramos, R. N., Piaggio, E., & Romano, E. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_11 · Cited by 34
Self-citationRole of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer
Park, S.-M., & Youn, J. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01165-6 · Cited by 34
Tan, L. Y., Martini, C., Fridlender, Z. G., Bonder, C. S., Brown, M. P., & Ebert, L. M. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2017.7 · Cited by 34
IFN-γ and CD38 in Hyperprogressive Cancer Development
Angelicola, S., Ruzzi, F., Landuzzi, L., Scalambra, L., Gelsomino, F., Ardizzoni, A., Nanni, P., Lollini, P., & Palladini, A. (2021) · Cancers · doi:10.3390/cancers13020309 · Cited by 34
James, J. L., Taylor, B. C., Axelrod, M. L., Sun, X., Guerin, L. N., Ericsson, P. I. G., Wang, Y., Sanchez, V. M., Fahey, C. C., Sanders, M. E., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007736 · Cited by 34
Brown, J. T., Liu, Y., Shabto, J. M., Martini, D. J., Ravindranathan, D., Hitron, E., Russler, G. A., Caulfield, S. E., Yantorni, L. B., Joshi, S. S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002851 · Cited by 34
Maccalli, C., Giannarelli, D., Capocefalo, F., Pilla, L., Fonsatti, E., Giacomo, A. M. D., Parmiani, G., & Maio, M. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1071007 · Cited by 33
Role of myeloid-derived suppressor cells in tumor recurrence
Cole, K., Al-Kadhimi, Z. S., & Talmadge, J. E. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10079-1 · Cited by 33
Wang, J. C. C., & Sun, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105837 · Cited by 33
Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma
Shen, S., Chen, L., Liu, J., Yang, L., Zhang, M., Wang, L., Zhang, R., Uemura, Y., Wu, Q., Yu, X., et al. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0027 · Cited by 33
Addressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need
Hu‐Lieskovan, S., Malouf, G. G., Jacobs, I. A., Chou, J., Liu, L., & Johnson, M. L. (2021) · Future Oncology · doi:10.2217/fon-2020-0967 · Cited by 32
Ezdoglian, A. A., Tsang-A-Sjoe, M. W. P., Khodadust, F., Burchell, G. L., Jansen, G., de Gruijl, T. D., Labots, M., & van der Laken, C. J. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10246-6 · Cited by 32
Radiation therapy and the innate immune response: Clinical implications for immunotherapy approaches
Gómez, V., Mustapha, R., Ng, K., & Ng, T. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14351 · Cited by 32
Xu, N., Huang, L., Li, X., Watanabe, M., Li, C., Xu, A., Liu, C., Li, Q., Araki, M., Wada, K., et al. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.32259 · Cited by 32
Shinoda, H., & Seto, H. (1985) · PubMed · Cited by 32
Liu, C., Zhou, F., Yan, Z., Shen, L., Zhang, X., He, F., Wang, H., Lu, X., Yu, K., Zhao, Y., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15457 · Cited by 32
Brown, J. T., Liu, Y., Shabto, J. M., Martini, D. J., Ravindranathan, D., Hitron, E., Russler, G. A., Caulfield, S. E., Yantorni, L. B., Joshi, S. S., et al. (2021) · The Oncologist · doi:10.1002/onco.13727 · Cited by 32
Metadata
- Authors
- Meyer, C., Cagnon, L., Costa-Nunes, C. M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E., & Speiser, D. E.
- Affiliations
- University of Lausanne (CH)
- Centre Hospitalier Universitaire Vaudois (CH)
- Corresponding author
- Speiser, Daniel E.
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2013-12-20
- Volume
- 63
- Issue
- 3
- Pages
- 247-257
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11029062
- OpenAlex
- W2080886891
- Cited by
- 560
- References
- 58
- Citations by year
- 2026: 12 · 2025: 37 · 2024: 29 · 2023: 59 · 2022: 64 · 2021: 73 · 2020: 85 · 2019: 49 · 2018: 36 · 2017: 36 · 2016: 33 · 2015: 25 · 2014: 18 · 2013: 1
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- reroDoc Digital Library (submittedVersion)
- IRIS (submittedVersion)
- Funders
- National Science Foundation
- Ludwig Institute for Cancer Research
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (141879, 135553, 310030)
- Fondation ISREC
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- myeloid-derived suppressor cells, metastatic melanoma, ipilimumab, CTLA-4 blockade, predictive biomarkers, treatment response, monocytic MDSCs, tumor resection, lactate dehydrogenase, immune monitoring
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Cell Count, Female, Humans, Immune Tolerance, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Skin Neoplasms, Treatment Outcome, Lipopolysaccharide Receptors, Myeloid Cells, Biomarkers, Pharmacological, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.